Mechanism and Application Strategy of Histone Modification in Targeted Therapy for Lung Cancer
DOI:
https://doi.org/10.54097/e5ddxd36Keywords:
Histone Modification; Lung cancer; Targeted Therapy.Abstract
Lung cancer is a global disease burden and severe malignant disease, which has been a major morbidity and mortality double burden. Current lung cancer treatment still suffers from severe problems, including drug resistance, high metastasis frequency, and tumor heterogeneity, and allows new therapeutic manner to be developed. Histone modification, which is the major epigenetic modification mechanism, has demonstrated great application potential of targeted therapy against lung cancer. This review systematically summarizes the central role of histone acetylation modification and methylation modification in the pathogenesis of lung cancer. Plus, it focuses on the mechanism of key enzymes such as HDAC and EZH2 to promote the malignant progression of tumors by gene expression as well as regulating chromatin structure. Research has established that inhibitors targeting these targets have yielded encouraging results in clinical studies, especially with the combination strategy of chemotherapy, targeted therapy and immunotherapy. However, challenges such as poor drug selectivity, epigenetic heterogeneity, and complex modification networks still need to be overcome. In the future, it is necessary to promote the clinical application of histone modification targeted interventions in the realm of precision treatment against lung cancer through interdisciplinary cooperation, combined with multi-omics analysis and new technical means.
Downloads
References
[1] Filho, A. M., Laversanne, M., Ferlay, J., Colombet, M., Piñeros, M., Znaor, A., Parkin, D. M., Soerjomataram, I., & Bray, F. (2025). GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. International journal of cancer, 156(7), 1336–1346. https://doi.org/10.1002/ijc.35278
[2] Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Di Federico, A., Gelsomino, F., & Ardizzoni, A. (2020). Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma. Critical reviews in oncology/hematology, 156, 103119. https://doi.org/10.1016/j.critrevonc.2020.103119
[3] Pathak, A., Tomar., Pathak S. (2023). Epigenetics and Cancer a Comprehensive Review. Asian Pac J Cancer Biol, 8 (1), 75-89. https : // www. researchgate.net/publication/ 370778055_Epigenetics_ and _ Cancer _ A _ Comprehensive _ Review.
[4] Chen, Y., Liu, X., Li, Y., Quan, C., Zheng, L., & Huang, K. (2018). Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges. Computational and structural biotechnology journal, 16, 211–223. https://doi.org/10.1016/j.csbj.2018.06.001
[5] Yang, M., Hu, X., Tang, B., & Deng, F. (2024). Exploring the interplay between methylation patterns and non-coding RNAs in non-small cell lung cancer: Implications for pathogenesis and therapeutic targets. Heliyon, 10(2), e24811. https://doi.org/10.1016/j.heliyon.2024.e24811
[6] Yan, H., Tang, L., Yuan, Z., & Zhang, Y. (2025). The effects of STAT3 acetylation on transcriptional activity and tumorigenesis. Biochemical pharmacology, 240, 117076. https : // doi.org/ 10.1016/ j.bcp.2025.117076
[7] Bu, S., Ye, T., Gao, H., Song, H. & Zhu, Y. (2025). Histone methylation and acetylation in cancer: mechanism, progression, and targets. Oncologie, 27(1), 29-43. https://doi.org/10.1515/oncologie-2024-0324
[8] Zhou, M., Yuan, M., Zhang, M., Lei, C., Aras, O., Zhang, X., & An, F. (2021). Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. European journal of medicinal chemistry, 226, 113825. https://doi.org/10.1016/j.ejmech.2021.113825
[9] Cao, Q., Zhao, L., & Wang, P. (2014). Zhongguo fei ai za zhi = Chinese journal of lung cancer, 17(7), 569–574. https://doi.org/10.3779/j.issn.1009-3419.2014.07.13
[10] Maldotti, M., Lauria, A., Anselmi, F., Molineris, I., Tamburrini, A., Meng, G., Polignano, I. L., Scrivano, M. G., Campestre, F., Simon, L. M., Rapelli, S., Morandi, E., Incarnato, D., & Oliviero, S. (2022). The acetyltransferase p300 is recruited in trans to multiple enhancer sites by lncSmad7. Nucleic acids research, 50(5), 2587–2602. https://doi.org/10.1093/nar/gkac083
[11] Chen, W., Duan, X., Zhu, X., Han, Y., Li, Y. (2025). Histone H1.4K75 acetylation promotes tumor growth and migration by regulating p53 and ERK1/2 pathway in non-small lung cancer. Biochemical and Biophysical Research Communications, 768, 151880. https://doi.org/10.1016/j.bbrc.2025.151880
[12] Sullivan, J. P., Spinola, M., Dodge, M., Raso, M. G., Behrens, C., Gao, B., Schuster, K., Shao, C., Larsen, J. E., Sullivan, L. A., Honorio, S., Xie, Y., Scaglioni, P. P., DiMaio, J. M., Gazdar, A. F., Shay, J. W., Wistuba, I. I., & Minna, J. D. (2010). Aldehyde dehydrogenase activity is selected for lung adenocarcinoma stem cells dependent on notch signaling. Cancer research, 70(23), 9937–9948. https://doi.org/10.1158/0008-5472.CAN-10-0881
[13] Zhou, X., Liu, X., Wan, X., Xu, M., Wang, R., Yang, D., Peng, M., Jin, T., Tang, R., Liu, M., & Hou, Y. (2024). Oxidized ATM governs stemness of breast cancer stem cell through regulating ubiquitylation and acetylation switch. Biochemical and biophysical research communications, 691, 149243. https://doi.org/10.1016/j.bbrc.2023.149243
[14] Hu, Y., Mu, H., & Deng, Z. (2023). H3K27 acetylation activated-CCS regulates autophagy and apoptosis of lung cancer by alleviating oxidative stress. Tissue & cell, 80, 101964. https://doi.org/10.1016/j.tice.2022.101964
[15] Audia, J. E., & Campbell, R. M. (2016). Histone Modifications and Cancer. Cold Spring Harbor perspectives in biology, 8(4), a019521. https://doi.org/10.1101/cshperspect.a019521
[16] Liu, Y., & Yang, Q. (2023). The roles of EZH2 in cancer and its inhibitors. Medical oncology (Northwood, London, England), 40(6), 167. https://doi.org/10.1007/s12032-023-02025-6
[17] Lv, Z., Ji, T., Liu, J., Sun, X., & Liang, H. (2025). Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: A review. European journal of medicinal chemistry, 283, 117185. https://doi.org/10.1016/j.ejmech.2024.117185
[18] Rossetto, D., Avvakumov, N., & Côté, J. (2012). Histone phosphorylation: chromatin modification involved in diverse nuclear events. Epigenetics, 7(10), 1098–1108. https://doi.org/10.4161/epi.21975
[19] Han, T., Wang, Y., Cheng, M., Hu, Q., Wan, X., Huang, M., Liu, Y., Xun, W., Xu, J., Wang, L., Luo, R., Yuan, Y., Wang, K., & Wang, J. (2024). Phosphorylated SHMT2 Regulates Oncogenesis Through m6A Modification in Lung Adenocarcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11(18), e2307834. https://doi.org/10.1002/advs.202307834
[20] Mamdani, H., & Jalal, S. I. (2020). Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?. Frontiers in cell and developmental biology, 8, 582370. https : // doi.org/ 10.3389 / fcell.2020. 582370.
[21] Zhu, S., He, Y., Wang, W., Jiao Y., Xu, Z., You, S., Yu, C., Ao J., Long M., Ren, J., Zhang, H., Liu, S., Bao, H., Wang, S. (2025). KAZN methylation as a potential diagnostic and prognostic marker in non-small cell lung cancer. iScience, 28(10), e24811. https://doi.org/10.1016/j.isci.2025.113585
[22] Cheng, B., Xu, X., Fan, B., Ma, T., & Yu, B. (2025). Epigenetic roles of lysine-specific demethylase 1 (LSD1) in cancer metabolism. Drug discovery today, 30(7), 104397. https : // doi.org/10.1016/j.drudis. 2025. 104397
[23] Hedayat, F., Faghfuri, E. (2025). Harnessing histone deacetylase inhibitors for enhanced cancer immunotherapy. European Journal of Pharmacology, 997, 177620. https: // doi.org/ 10.1016/ j.ejphar.2025.177620
[24] Lv, Z., Ji, T., Liu, J., Sun, X., & Liang, H. (2025). Synthetic approaches and clinical applications of representative HDAC inhibitors for cancer therapy: A review. European journal of medicinal chemistry, 283, 117185. https://doi.org/10.1016/j.ejmech.2024.117185
[25] Xu, Y., Meng, Y., Xu, Y., Han, J., & Zhu, Q. (2025). Epigenetic mechanisms in non-small cell lung cancer therapy and chemoresistance. Biochimica et biophysica acta. Reviews on cancer, 1880(4), 189356. https://doi.org/10.1016/j.bbcan.2025.189356.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
